肝胆相照论坛

标题: 核酸聚合物和进入抑制剂在乙肝病毒功能性治疗策略中的作 [打印本页]

作者: StephenW 时间: 2020-12-21 19:51 标题: 核酸聚合物和进入抑制剂在乙肝病毒功能性治疗策略中的作

Role of Nucleic Acid Polymers and Entry Inhibitors in Functional Cure Strategies for HBV

Sasan Sakiani, Bilal Asif, Alexander Yang & Christopher Koh

Current Hepatology Reports volume 19, pages370–381(2020)Cite this article

29 Accesses

Metrics details

Abstract
Purpose of Review

Hepatitis B virus (HBV) infection is one of the most common viral infections worldwide with an estimated 2 billion people exposed to HBV and 240 million with active chronic infection. Despite this, less than 1% of patients with chronic HBV infection receive treatment, and less than 3% of those achieve functional cure with traditional therapies. This review summarizes recent advances in the treatment of chronic HBV utilizing nucleic acid polymers (NAP) and entry inhibitors (EI).
Recent Findings

A recent phase 2 study evaluating the use of NAP following tenofovir and pegylated interferon (PEG-IFN) demonstrated increased rates of functional cure which persisted in 35% of patients after 48 weeks of follow-up. In addition, the EI Myrcludex B has demonstrated HBsAg response in up to 40% of patients when used in combination with PEG-IFN at week 72.
Summary

Functional cure is considered the “holy grail” of treatment, and many new therapies are under investigation for the treatment of chronic HBV. As we work towards functional cure for chronic HBV, NAPs and EIs have shown efficacy in reducing HBV DNA and HBsAg levels and have emerged as potential therapeutic agents that may lead to a functional cure for HBV.

作者: StephenW 时间: 2020-12-21 19:51

核酸聚合物和进入抑制剂在乙肝病毒功能性治疗策略中的作用

Sasan Sakiani，Bilal Asif，Alexander Yang和Christopher Koh

《现行肝病学报告》第19卷，第370–381页（2020年）

29次访问

指标详细信息

抽象
审查目的

乙型肝炎病毒（HBV）感染是全球最常见的病毒感染之一，估计有20亿人接触HBV，2.4亿人患有活动性慢性感染。尽管如此，只有不到1％的慢性HBV感染患者得到治疗，只有不到3％的患者通过传统疗法达到功能治愈。这篇综述总结了利用核酸聚合物（NAP）和进入抑制剂（EI）治疗慢性HBV的最新进展。
最近的发现

一项最新的2期研究评估了替诺福韦和聚乙二醇干扰素（PEG-IFN）后使用NAP的使用，表明功能治愈率提高了，在48周的随访后，仍有35％的患者得以治愈。此外，EI Myrcludex B在第72周与PEG-IFN组合使用时，已显示多达40％的患者对HBsAg有反应。
概要

功能性治疗被认为是治疗的“圣杯”，许多新的治疗方法正在研究中，以治疗慢性HBV。随着我们努力进行慢性HBV的功能性治疗，NAP和EIs已显示出降低HBV DNA和HBsAg水平的功效，并已成为可能导致HBV功能性治疗的潜在治疗剂。

作者: newchinabok 时间: 2020-12-22 09:57

StephenW 发表于 2020-12-21 19:51
核酸聚合物和进入抑制剂在乙肝病毒功能性治疗策略中的作用

Sasan Sakiani，Bilal Asif，Alexander Yan ...

sw老师，rep+干挠素，你是用不成的

欢迎光临肝胆相照论坛 (http://hbvhbv.info/forum/)